调节性细胞过继回输在器官移植中的研究及应用进展  

Research and application progress in adoptive re-transfusion of regulatory cells in organ transplantation

作　　者：王若麟 贾亚男 朱继巧[1] 贺强[1] 李先亮[1] Wang Ruolin;Jia Ya’nan;Zhu Jiqiao;He Qiang;Li Xianliang(Department of Hepatobiliary-pancreatic-splenic Surgery,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院肝胆胰脾外科,北京100020

出　　处：《器官移植》2023年第6期892-897,共6页Organ Transplantation

基　　金：北京市自然科学基金面上项目(7232068);北京市朝阳医院科技创新基金(21kcjj-4)。

摘　　要：排斥反应和长期使用免疫抑制药所带来的不良反应严重影响器官移植受者的生存率和生活质量,诱导免疫耐受是提高器官移植受者生存率,改善生活质量的关键。近年来,调节性细胞过继回输治疗取得了巨大的进展。本文就调节性T细胞(Treg)、髓源性抑制细胞(MDSC)以及调节性B细胞(Breg)在动物实验及临床应用中的进展进行综述,并总结调节性细胞过继回输临床上所面临的主要问题、嵌合抗原受体Treg的应用情况及免疫评估的细胞治疗概念,以期加深广大研究者对调节性细胞治疗的理解,促进调节性细胞在器官移植免疫耐受中的应用,改善器官移植效果和受者生存质量。Rejection and adverse reactions caused by long-term use of immunosuppressants severely affect the survival rate and quality of life of organ transplant recipients.Immune tolerance induction plays a key role in improving the survival rate and quality of life of organ transplant recipients.In recent years,tremendous progress has been achieved in adoptive re-transfusion of regulatory cells.In this article,research progress in regulatory T cell(Treg),myeloid-derived suppressor cell(MDSC)and regulatory B cell(Breg)in animal experiment and clinical application was reviewed,and the main clinical problems of adoptive re-transfusion of regulatory cells,the application of chimeric antigen receptor Treg and the concept of cell therapy in immune evaluation were summarized,aiming to deepen the understanding of regulatory cell therapy,promote the application of regulatory cells in immune tolerance of organ transplantation,and improve clinical efficacy of organ transplantation and the quality of life of recipients.

关 键 词：器官移植 免疫耐受 排斥反应 细胞治疗 调节性T细胞 调节性B细胞 髓源性抑制细胞 嵌合抗原受体 

分 类 号：R617[医药卫生—外科学] R392.4[医药卫生—临床医学]